ESR1 and breast cancer: Profiling of CTC’s from metastatic breast cancer patients has also highlighted the intra-TH of ESR1 mutations in patients with endocrine resistance suggesting independent mechanisms of resistance to these agents, and highlighting the clinical applicability of single-cell approaches for detecting genomic alterations mediating targeted therapy resistance91.